title: [Effect of abdominal obesity on size of myocardial infarction].
abstract: OBJECTIVE
  Metabolic syndrome consists of a group of factors that predict the risk of having an acute cardiovascular event. Some of these factors increase the risk of myocardial infarction and are also associated with the severity of cardiovascular events. The objective was to determine the influence of factors associated with metabolic syndrome, and especially abdominal obesity, on the size of coronary events, estimated by the concentration of total creatine phosphokinase (CPK) and CPK-MB isoenzyme (CPK-MB).
  
  
  METHODS
  We performed a cross-sectional study of 40 men diagnosed with acute coronary syndrome. We collected clinical data (age, history of diabetes, dyslipidemia and hypertension ) and anthropometric data [body mass index (BMI), waist circumference (WC) and waist-to-height ratio (WHR)]. CPK and CPK-MB concentrations were measured to determine the maximum concentration reached in order to estimate the size of the myocardial infarction area.
  
  
  RESULTS
  The prevalence of metabolic syndrome was 30%. Approximately 84% of the patients were overweight and 42% had abdominal obesity. A positive association was found between myocardial enzymes and anthropometric parameters (BMI, WC, WHR). The variable showing the closest association with the size of myocardial infarction was central obesity [total CPK, r (Pearson) = 0.47; p<0.003] and (CPK-MB, r= 0.4; p<0.01). Metabolic syndrome was not a predictive factor for the size of myocardial necrosis (beta=-0.29; p<0.1). Multiple regression analysis showed that WC predicted maximal total CPK (beta=37.15; 95% CI, 9.16-65.15; p<0.01) and CPK-MB concentrations (beta=5.7; 95% CI, -0.4-11.9; p< 0.06) after an acute coronary event.
  
  
  CONCLUSIONS
  The presence of abdominal obesity was associated with greater myocardial necrosis size after an acute coronary event.
authors.affiliation: Servicio de Endocrinología y Nutrición, Hospital Universitario de Getafe, Carretera de Toledo Km 12,500, 28905 Getafe, España. paloma_i_b@yahoo.es
authors.forename: Paloma
authors.initials: P
authors.lastname: Iglesias Bolaños
authors.forename: Juana
authors.initials: J
authors.lastname: Olivar Roldán
authors.forename: David
authors.initials: D
authors.lastname: Peñalver Talavera
authors.forename: Patricia
authors.initials: P
authors.lastname: Díaz Guardiola
authors.forename: Belén
authors.initials: B
authors.lastname: Vega Piñero
authors.forename: Susana
authors.initials: S
authors.lastname: Monereo Megías
mesh_terms: D050153:Abdominal Fat / Q000473:pathology*; D054058:Acute Coronary Syndrome / Q000097:blood / Q000150:complications / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000886:Anthropometry; D001786:Blood Glucose / Q000032:analysis; D003402:Creatine Kinase / Q000097:blood; D052279:Creatine Kinase, MB Form / Q000097:blood; D003430:Cross-Sectional Studies; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000453:epidemiology / Q000473:pathology; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications / Q000473:pathology*; D009336:Necrosis; D009765:Obesity / Q000150:complications*; D015995:Prevalence; D012307:Risk Factors; D055105:Waist Circumference
chemical_list: D001786:Blood Glucose; D003402:Creatine Kinase; D052279:Creatine Kinase, MB Form